LLY vs PFE: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
PFE |
| Current Price |
$1,179.09 |
$25.22 |
| Fair Value Estimate |
$1,552.32 |
$25.92 |
| Upside to Fair Value |
+31.7%
|
+2.8%
|
| Market Cap |
$1,110.4B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
34.3x
|
12.3x
|
| Price / Sales |
14.6x
|
2.3x
|
| Price / FCF |
77.7x
|
15.2x
|
| Revenue Growth YoY |
+55.5%
|
+5.4%
|
| Gross Margin |
83.5%
|
69.3%
|
| Operating Margin |
45.9%
|
23.4%
|
| Return on Equity |
101.3%
|
8.4%
|
| Dividend Yield |
0.55% |
0% |
| FCF Yield |
1.29%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
LLY |
PFE |
| Zone Low |
$1,164.24 |
$19.44 |
| Zone High |
$1,319.47 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|